Results 21 to 30 of about 158,005 (297)
Actual issues of lipid centers’ operation in Russian Federation
Кардиоваскулярная терапия и профилактика, 2021 .
S. Boytsov +10 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background Cardiovascular disease is the leading cause of morbidity and mortality with incidence rates of 5–10 per 1000 person-years, according to primary prevention studies.
Hsin-Yin Hsu +4 more
doaj +1 more source
American Heart Journal Plus, 2022 Study objective: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline recommends a maximally-tolerated statin with add-on lipid-lowering therapy, ezetimibe and/or proprotein convertase subtilisin/kexin type 9
Chibuike J. Alanaeme +14 more
doaj +1 more source
Combined lipid-lowering therapy [PDF]
Vnitřní lékařství, 2018 Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of ...
openaire +2 more sources
Lipid-lowering for lower limb atherosclerosis [PDF]
, 2007 Background: Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovascular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD ...
Price, Jackie +9 more
core +1 more source
Cardiology Research and Practice, 2020 Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive ...
Ze-Min Kuang
doaj +1 more source
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Reviews in Cardiovascular Medicine, 2022 Lipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines.
Ying Xiao +7 more
doaj +1 more source
Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]
, 2014 The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones +13 more
core +1 more source
Cardiovascular Diabetology, 2017 Background Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic ...
Markolf Hanefeld +3 more
doaj +1 more source
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview [PDF]
Diabetes & Metabolism Journal, 2023 Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes ...
Sang Heon Suh, Soo Wan Kim
doaj +1 more source